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Abstract 
Background: Circulating tumor cells (CTCs) play a crucial role in tumor dissemination and are 
prognostic in primary and metastatic breast cancer. Peripheral blood (PB) immune cells contribute to an 
unfavorable microenvironment for CTC survival. This study aimed to correlate CTCs with the PB T-cell 
immunophenotypes and functions of patients with inflammatory breast cancer (IBC). 
Methods: This study included 65 IBC patients treated at the MD Anderson Cancer Center. PB was 
obtained from patients prior to starting a new line of chemotherapy for CTCs enumeration by 
CellSearch®, and T cell phenotype and function by flow cytometry; the results were correlated with 
CTCs and clinical outcome.  
Results: At least 1 CTC (≥1) or ≥5 CTCs was detected in 61.5% or 32.3% of patients, respectively. 
CTC count did not correlate with total lymphocytes; however, patients with ≥1 CTC or ≥5 CTCs had 
lower percentages (%) of CD3+ and CD4+ T cells compared with patients with no CTCs or <5 CTCs, 
respectively. Patients with ≥1 CTC had a lower percentage of T-cell receptor (TCR)-activated CD8+ T 
cells synthesizing TNF-α and IFN-γ and a higher percentage of T-regulatory lymphocytes compared to 
patients without CTCs. In multivariate analysis, tumor grade and % CD3+ T-cells were associated with 
≥1 CTC, whereas ≥5 CTC was associated with tumor grade, stage, % CD3+ and % CD4+ T cells, and 
% TCR-activated CD8 T-cells synthesizing IL-17. 
Conclusions: IBC patients with CTCs in PB had abnormalities in adaptive immunity that could 
potentially impact tumor cell dissemination and initiation of the metastatic cascade. 
Key words: Circulating tumors cells, adaptive immunity, and inflammatory breast cancer 
Introduction 
Inflammatory breast cancer (IBC) is one of the 
most aggressive forms of breast cancer, and its 
incidence is approaching 5% of all breast cancers [1-3]. 
The prognosis of IBC patients remains poor with a 
10-year disease-free survival rate of only 20-25%, 
despite a multimodality treatment approach [4-9]. The 
disease is associated with resistance to standard 
therapies and early metastatic dissemination. These 
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unsatisfactory results emphasize the need for a better 
understanding of the molecular aspects of this disease 
in order to improve outcome of IBC patients. 
Metastatic disease is a major cause of death of 
breast cancer patients. The metastatic cascade consists 
of a series of biological steps that enables tumor cells 
to detach from the primary tumor, invade the blood 
venules to traverse the peripheral circulation, 
extravasate into the parenchyma and establish a new 
tumor [10]. Metastatic cascade is a highly inefficient 
process and only a minimal number of tumor cells 
that enter the blood circulation are capable of forming 
metastases [11-13]. Circulating tumor cells (CTCs) 
play a crucial role in metastatic cascade and are a 
prognostic factor in patients with primary [14] and 
metastatic breast cancer (MBC) [15]. Recently, we 
reported that CTCs can be detected in a large 
proportion of patients with newly diagnosed IBC and 
are a strong predictor of worse prognosis in patients 
with newly diagnosed IBC [16]. 
Peripheral blood (PB) represents a highly 
unfavorable microenvironment for the survival of 
CTCs owing to physical forces, the presence of 
immune cells, and anoikis, which collectively 
contribute to metastatic insufficiency [17,18]. More 
specifically, effective host innate and adaptive 
immune surveillance systems could adversely retard 
tumor dissemination whereas dysfunctional immune 
systems might provide a favorable microenvironment 
for the dissemination of CTCs and their survival in 
circulation, ultimately leading to cancer progression 
[19].  
Current data concerning relationship between 
CTCs and the immune system in breast cancer are 
limited. Previous studies suggested, that MBC 
patients with ≥5 CTCs per 7.5 mL of peripheral blood 
had significantly decreased natural killer (NK) cells 
function compared to patients with <5 CTCs [20]. 
Similarly, differences in expression of toll-like 
receptors (TLR) on immune cells were observed in 
MBC patients based on presence or absence of CTCs 
[21]. In non-metastatic breast cancer, patients with 
CTCs had a significant increase of peripheral 
CD95(FAS)-positive T-helper cells [22]. As the host 
immune response is regulated by 
CD95(APO-1/FAS)-CD95ligand interaction and 
apoptosis of cancer cells is induced via the 
CD95/CD95L pathway, it is supposed that this could 
lead to tumor cell escape by apoptotic T-helper cells 
[22]. 
T cells play a key role in the adaptive immune 
response. Thus, we hypothesize that patients with IBC 
with detectable CTCs exhibit deficits in adaptive 
immunity including a decrease in number and 
function of T-helper and cytotoxic T cells as well as an 
increase of immunosuppressive T-regulatory cells. 
The connection between CTCs and innate and 
adaptive immunity in patients with IBC has never 
been examined. In this translational study, we aimed 
to correlate CTCs with the status and functions of 
adaptive (T cells) immune effector cells in PB of 
patients with IBC. 
Patients and Methods 
Study patients 
The Institutional Review Board (IRB) of The 
University of Texas MD Anderson Cancer Center 
approved protocol LAB08-0199 (Chair, J. Reuben) to 
conduct this prospective translational study. A 
population of consecutive patients, who signed 
informed consent, with locally advanced or metastatic 
IBC treated from October 2008 through April 2012, 
was eligible. Patients underwent systemic therapy as 
appropriate for their malignancies, irrespective of the 
presence of CTCs or CTC count. Patients with a 
concurrent malignancy other than nonmelanoma skin 
cancer in the previous 5 years were excluded.  
All patients underwent pretreatment diagnostic 
biopsy. The diagnosis of IBC was based on clinical 
signs such as diffuse erythema, peau d'orange, 
tenderness, induration, and warmth [23,24]. The 
presence of dermal lymphatic emboli in the diagnostic 
pathology report was not mandatory for the 
pathological diagnosis of IBC. Clinical stage at 
diagnosis of primary disease was coded according to 
the criteria set forth in the sixth edition of the 
American Joint Committee on Cancer’s AJCC Cancer 
Staging Manual [25]. 
Data regarding age, tumor histologic subtype, 
hormone receptor status, HER2 amplification status, 
type and number of sites of metastasis, and delivery 
of systemic therapy were recorded in all the patients 
and compared with the presence and number of CTCs 
and immune cells profiling. Normal donors (N = 34) 
were age-matched women without breast cancer who 
were recruited and consented according to the 
IRB-approved protocol. 
Detection of CTCs in peripheral blood 
The CellSearch system (Veridex Corporation, 
Warren, NJ) was used to detect and enumerate CTCs 
in 7.5 mL of whole peripheral blood. Samples were 
subjected to enrichment of epithelial cells with 
anti-EpCAM-coated ferrous particles. CTCs were 
defined as nucleated cells (DAPI+) lacking surface 
expression of the leukocyte antigen (CD45) and 
having cytoplasmic expression of cytokeratin 8, 18, or 
19 [26]. Specimens were stored at room temperature 
and processed within 1 day of phlebotomy. CTCs 
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were detected in patients before starting a new line of 
chemotherapy. 
Immune monitoring of patients 
From each patient, we obtained peripheral blood 
for the enumeration of CTCs and immune monitoring. 
All blood samples for CTCs as well as for immune cell 
analysis were collected at the same time before 
starting the new line of chemotherapy. Atraumatic 
venous blood sampling was performed at the 
antecubital fossa and patients provided 27 mL of 
peripheral blood for immune evaluation that included 
leukocyte immunophenotyping and cytokine 
syntheses by individual T cells activated through the 
T-cell receptor (TCR) using immobilized anti-CD3 
antibody and soluble anti-CD28 as costimulator, as 
previously described [27].  
T-cells subsets enumeration and cytokine 
synthesis by anti-CD3 activated T cells 
Subsets of T cell subsets [CD4, CD8, and 
T-regulatory (Treg)] were determined by 
multi-parameter flow cytometry, as described 
previously [28]. Intracellular cytoplasmic syntheses of 
interleukin (IL)-2, IL-4, IL-10, IL-17, interferon-gamma 
(IFN-γ), and tumor necrosis factor-alpha (TNF-α) by 
TCR-activated T cells were measured by a flow 
cytometric assay, as described previously [27,29]. 
Statistical analysis 
Patient characteristics were tabulated and 
summarized using the median (range) for continuous 
variables and frequency (percentage) for categorical 
variables. Normality of distribution was tested by the 
Kolmogorov-Smirnov test. If data were normally 
distributed, sample means were tested by Student 
t-test or analysis of variance. For non-normally 
distributed data, the nonparametric Mann-Whitney U 
test or Kruskal-Wallis H test was used. Pearson's or 
Spearman's correlation was used according to the 
normality of the data. 
Baseline CTC count was defined as the earliest 
CTC measurement obtained before the start of a new 
line of therapy. We dichotomized baseline CTC 
counts using two different thresholds: as <1 or ≥1 and 
as <5 or ≥5 per 7.5 mL of peripheral blood. The cut-off 
at 1 CTCs was chosen because it has been investigated 
in other settings, such as in primary breast cancer, 
including locally advanced and inflammatory breast 
cancer [14,16,30-34]. The cut-off at 5 CTCs was shown 
to be prognostic for progression free survival (PFS) 
and overall survival (OS) in patients with metastatic 
breast cancer [15] as well as in IBC patients [16, 34].  
Univariate analyses with Chi squared or the 
Fisher’s exact test were performed to assess 
association between immune cells and CTC status 
followed by multivariate logistic regression analysis 
that included baseline CTC counts, immune cells, 
hormone receptor status (positive for either or 
negative for both), HER-2 status (overexpressed or 
negative), tumor grade (1 and 2 vs. 3), and tumor 
stage (stage III IBC vs. metastatic IBC), respectively. A 
backward model selection was conducted, and the 
final fitted model is shown in Tables 4 and 5. 
We correlated baseline CTC counts and different 
subpopulations of immune cells with OS. For survival 
analysis, immune cell percentages were dichotomized 
to “low” or “high” category using the median count of 
all study patients. Median follow-up period was 
calculated as a median observation time among all 
patients and among those still alive at the time of their 
last follow-up. OS was calculated from the date of 
baseline CTC enumeration to the date of death or last 
follow-up. OS was estimated using the Kaplan-Meier 
product-limit method and compared between groups 
using the log-rank test. A multivariate Cox 
proportional hazards model for OS was used to assess 
differences in outcome on the basis of baseline CTC 
counts, immune cells, hormone receptor status, HER-2 
status, and tumor grade and stage. Step-wise 
regression techniques were used to build multivariate 
models using a significance level of 0.10 to remain in 
the model. All statistical tests were 2-sided, and P 
values <0.05 were considered statistically significant. 
Results 
Patients’ characteristics 
This prospective study included 65 patients with 
IBC (21 stage III IBC, 14 de novo metastatic and 30 
recurrent metastatic IBC) treated between October 
2008 and April 2012 at the MD Anderson Cancer 
Center. Thirty-five (53.9%) patients were treatment 
naïve at the time of blood collection. The median age 
of the study subjects was 54 years (range, 33-76 years). 
Fifty-eight (89.2%) patients were of Caucasian origin. 
Patients’ characteristics are shown in Table 1. Median 
baseline CTC count was 2 (range, 0-211) per 7.5 mL of 
PB. Among the 65 patients with IBC, 40 patients 
(61.5%) had a CTC count of ≥1 and 21 (32.3%) ≥5. The 
proportion of patients with IBC with ≥1 CTC was 
lower in those with stage III than in metastatic (mIBC) 
IBC (33.3% vs 75.0%; P = 0.002); the proportion of 
patients with stage III IBC with ≥5 CTCs was also 
lower than for patients with mIBC (5.0% vs 45.5%; P = 
0.001).  
T-cell subsets in IBC patients and normal 
donors  
Patients with IBC (stage III IBC plus mIBC) had a 
significantly lower absolute lymphocyte count (ALC) 
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and percentage of lymphocytes than those of normal 
donors. The severe decrease in the ALC of patients 
was associated with stage of disease such that those 
with mIBC had a lower ALC than that of patients with 
stage III IBC (Table 2). Treatment naïve patients with 
mIBC had a non-significantly higher lymphocyte 
percentage compared to that of patients with 
pretreated mIBC (27.5 ± 2.0 vs. 21.4 ± 1.8, p = 0.06), but 
still significantly lower compared to that of normal 
donors (27.5 ± 2.0 vs. 32.7 ± 1.4, p = 0.04). 
Additionally, lymphocyte immunophenotype 
analysis indicated that patients with stage III IBC had 
higher, while patients with mIBC had lower 
percentages of total T cells (CD3+) and CD3+CD4+ 
(helper) T-cell subset, compared with those of healthy 
normal donors. Nevertheless, among the CD3+CD4+ 
T-cell subset, patients with mIBC had a higher 
percentage of T-regulatory lymphocytes than both 
patients with stage III IBC and healthy normal donors.  
Twenty-four patients included in the study were 
HER2 positive, and 9 (37.5%) of them were pretreated 
with trastuzumab-based chemotherapy. Trastuzumab 
is known to activate both the innate and the adaptive 
immune systems as well as to be capable of inducing 
long-lasting immune responses by reducing 
circulating T regulatory cells [35,36]. However, there 
was not a significant difference in any of the analyzed 
T-cell subsets in patients with mIBC based on 
previous treatment, except ALC, that was 
significantly higher in patients with prior to 
trastuzumab treatment in contrast to patients who 
were pretreated with chemotherapy without 
trastuzumab (p = 0.04). Patients with prior 
trastuzumab treatment had significantly lower 
percentages of CD3+ CD4+ T cells (p = 0.01) and 
CD3+ CD8+ T-cells that synthesized IFN-γ (p=0.03) 
and a higher percentage of CD3+ CD8+ T 
lymphocytes (p = 0.03), compared with patients who 
had received other chemotherapy agents or no 
therapy at all. 
Table 1. Clinicopathological characteristics of patients with IBC 
(n = 65)  
 Stage III IBC mIBC 
 N % N % 
All 21 100.0 44 100.0 
CTC per 7.5 mL of blood     
 ≥ 1 7 33.3 33 75.0 
 ≥ 5 1 4.8 22 50.0 
Grade     
 1 and 2 9 42.9 14 31.8 
 3 12 57.1 29 65.9 
 unknown 0 0.0 1 2.3 
Histology     
 Invasive ductal carcinoma 18 85.7 36 81.8 
 Other 3 14.3 8 18.2 
Hormone receptor status     
 Negative for both 6 28.6 24 54.5 
 Positive for either 15 71.4 20 45.5 
HER2 status     
 Amplified 10 47.6 14 31.8 
 Normal 11 52.4 30 68.2 
ER/PR and HER2/neu status     
 Triple receptor negative 5 23.8 17 38.6 
 Non-triple receptor negative 16 76.2 27 61.4 
Sites of metastases     
 Non-visceral NA NA 27 61.4 
 Visceral NA NA 17 38.6 
Bone metastases     
 Present NA NA 23 52.3 
 Absent NA NA 21 47.7 
No. of metastasis     
 1 NA NA 21 47.7 
 ≥2 NA NA 23 52.3 
Treatment     
 Treatment naïve 21 100.0 14 31.8 
 Pretreated 0 0.0 30 68.2 
 
Table 2. Association between IBC and different subpopulations of T cells and their function  
Variable ND (N = 34) IBC  
(N = 21) 
P - 
value 1 
mIBC  
(N = 44) 
P - 
value 2 
P -  
value 3 
All IBCa 
(N = 65) 
P - 
value 4 
White blood cells k/μL 6.9 ± 0.4 b 7.4 ± 0.4 0.10 6.7 ± 0.4 0.89 0.17 6.9 ± 0.3 0.55 
Absolute lymphocytes count k/μL 2.2 ± 0.1 2.0 ± 0.1 0.31 1.5 ± 0.1 <0.001 0.004 1.7 ± 96.3 <0.001 
         
Lymphocytes (%) c 32.6 ± 1.5 27.7 ± 1.5 0.01 23.3 ± 1.3 <0.001 0.07 24.7 ± 1.1 <0.001 
CD3+  75.2 ± 1.3 80.3 ± 1.4 0.002 74.6 ± 1.2 0.73 0.01 76.4 ± 1.0 0.26 
         
CD3+ CD4+  47.7 ± 1.7 53.3 ± 1.7 0.01 44.6 ± 1.5 0.21 0.002 47.4 ± 1.2 0.88 
CD3+ CD8+ 21.6 ± 1.7 21.4 ± 1.6 0.62 25.0 ± 1.5 0.46 0.23 23.8 ± 1.2 0.74 
CD4/CD8 ratio 2.5 ± 0.3 3.0 ± 0.3 0.24 2.4 ± 0.2 0.52 0.14 2.6 ± 0.2 0.98 
Treg in CD4+ 6.9 ± 0.3 6.6 ± 0.4 0.52 7.7 ± 0.3 0.04 0.03 7.3 ± 0.2 0.23 
         
CD3+ CD4+ IFN-γ 9.0 ± 1.2 12.6 ± 1.3 0.07 9.1 ± 1.0 0.95 0.06 10.3 ± 0.8 0.39 
CD3+ CD4+ TNF-α 22.4 ± 2.2 24.4 ± 2.4 0.55 19.9 ± 2.0 0.20 0.19 21.4 ± 1.6 0.52 
CD3+ CD4+ IL-2 15.1 ± 1.8 16.6 ± 1.8 0.62 14.0 ± 1.7 0.37 0.15 14.9 ± 1.3 0.68 
CD3+ CD4+IL-4 2.9 ± 0.3 2.1 ± 0.3 0.04 2.2 ± 0.3 0.02 0.90 2.2 ± 0.2 0.01 
CD3+ CD4+ IL-10 5.6 ± 0.9 6.1 ± 1.0 0.99 5.3 ± 0.7 0.57 0.81 5.6 ± 0.6 0.69 
CD3+ CD4+ IL-17 2.8 ± 0.3 2.5 ± 0.3 0.41 2.7 ± 0.3 0.67 0.77 2.7 ± 0.2 0.50 
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CD3+ CD8+ IFN-γ 11.2 ± 1.6 18.8 ± 1.9 0.01 10.3 ± 1.2 0.65 0.001 13.3 ± 1.1 0.37 
CD3+ CD8+ TNF-α 12.6 ± 1.7 15.3 ± 1.9 0.27 10.2 ± 1.4 0.22 0.02 12.0 ± 1.2 0.70 
CD3+ CD8+ IL-2 6.4 ± 1.2 7.3 ± 1.3 0.17 6.0 ± 1.0 0.71 0.14 6.4 ± 0.8 0.73 
CD3+ CD8+IL-4 1.2 ± 0.2 1.4 ± 0.3 0.93 1.0 ± 0.1 0.31 0.48 1.1 ± 0.1 0.45 
CD3+ CD8+IL-10 4.7 ± 0.6 4.8 ± 0.8 0.77 3.3 ± 0.5 0.01 0.11 3.8 ± 0.4 0.05 
CD3+ CD8+IL-17 1.1 ± 0.3 2.0 ± 0.3 0.23 1.4 ± 0.2 0.64 0.40 1.6 ± 0.2 0.39 
Abbreviations: ND, normal donors; IBC, stage III inflammatory breast cancer; mIBC, metastatic IBC; a All IBC = IBC + mIBC; b Mean ± SEM (standard error of the mean); c all 
immune cells data are presented as percentage except otherwise specified; 1ND vs. IBC, 2ND vs. mIBC, 3IBC vs. mIBC, 4ND vs. IBC+mIBC  
 
Table 3. Association between CTCs and different subpopulations of T-cells and their function 
Variable CTC < 1 
Mean ± SEM 
CTC ≥ 1 
Mean ± SEM 
P - value CTC < 5 
Mean ± SEM 
CTC ≥ 5 
Mean ± SEM 
P - value 
White blood cells k/uL  6.6 ± 0.5 7.1 ± 0.38 0.24 6.8 ± 0.37 7.1 ± 0.53 0.45 
Absolute lymphocytes count k/μL 1.7 ± 0.2 1.7 ± 0.1 0.92 1.6 ± 0.1 1.8 ± 0.2 0.54 
       
%Lymphocytes * 26.9 ± 1.9 22.3 ± 1.5 0.11 24.9 ± 1.4 24.3 ± 2.1 0.53 
%CD3+  80.2 ± 1.6 74.2 ± 1.3 0.01 78.3 ± 1.2 72.7 ± 1.8 0.004 
       
CD3+ CD4+  50.9 ± 2.2 45.3 ± 1.7 0.07 49.5 ± 1.6 43.3 ± 2.3 0.05 
CD3+ CD8+  24.3 ± 2.4 23.5 ± 1.8 0.42 23.6 ± 1.8 24.2 ± 2.5 0.96 
CD4/CD8 ratio  2.5 ± 0.3 2.6 ± 0.3 0.90 2.7 ± 0.3 2.3 ± 0.4 0.92 
Treg in CD4+  6.8 ± 0.4 7.7 ± 0.3 0.05 7.1 ± 0.3 7.8 ± 0.4 0.15 
       
CD3+ CD4+ IFN-γ 11.0 ± 1.4 9.8 ± 1.1 0.51 10.8 ± 1.1 9.1 ± 1.5 0.50 
CD3+ CD4+ TNF-α  23.2 ± 2.5 20.2 ± 2.1 0.40 22.1 ± 2.0 20.0 ± 2.8 0.58 
CD3+ CD4+ IL-2 17.0 ± 2.1 13.5 ± 1.7 0.26 15.4 ± 1.6 14.0 ± 2.3 0.62 
CD3+ CD4+IL-4 1.8 ± 0.3 2.4 ± 0.3 0.16 2.1 ± 0.3 2.3 ± 0.4 0.95 
CD3+ CD4+ IL-10 5.5 ± 1.0 5.6 ± 0.8 0.62 6.2 ± 0.8 4.4 ± 1.1 0.19 
CD3+ CD4+ IL-17 2.4 ± 0.3 2.9 ± 0.3 0.16 2.5 ± 0.3 2.9 ± 0.4 0.20 
       
CD3+ CD8+ IFN-γ 16.2 ± 1.8 11.2 ± 1.5 0.08 13.6 ± 12.6 11.5 ± 2.1 0.87 
CD3+ CD8+ TNF-α 14.9 ± 1.8 10.0 ± 1.5 0.03 12.3 ± 1.4 11.3 ± 2.1 0.65 
CD3+ CD8+ IL-2 7.8 ± 1.3 5.5 ± 1.0 0.26 6.3 ± 1.0 6.7 ± 1.4 0.58 
CD3+ CD8+IL-4 1.2 ± 0.2 1.1 ± 0.2 0.79 1.1 ± 0.2 1.1 ± 0.2 0.70 
CD3+ CD8+IL-10 3.3 ± 0.7 4.2 ± 0.6 0.61 3.8 ± 0.6 3.8 ± 0.8 0.45 
CD3+ CD8+IL-17 1.6 ± 0.3 1.6 ± 0.3 0.70 1.4 ± 0.3 2.0 ± 0.4 0.05 
Abbreviations: SEM, standard error of the mean; *all immune cell data are presented as percentage, except otherwise specified  
 
 
Ability of CD4+ and CD8+ T-cell subsets to 
synthesize cytokines 
CD4+ and CD8+ T-cell subsets were assessed for 
their ability to synthesize cytokines (IL-2, IL-4 IL-10, 
IL-17, IFN-γ and TNF-α) following activation through 
the TCR with immobilized anti-CD3 antibody and 
soluble anti-CD28 costimulatory factor. Both cohorts 
of patients with IBC (stage III IBC, p = 0.04; and mIBC, 
p = 0.02) had a lower percentage of TCR-activated 
CD4+ T-cells that synthesized IL-4 compared with 
those of normal donors. Whereas patients with stage 
III IBC had a higher percentage of TCR-activated 
CD8+ T cells that synthesized IFN-γ than those of 
normal donors and those of patients with mIBC, the 
percentage of TCR-activated CD8+ T cells that 
synthesized IL-10 was lower in patients with mIBC 
than in both healthy normal donors and patients with 
stage III IBC (Table 2).  
Association between CTCs and percentage of 
different T cell subsets 
There was no correlation between the CTC count 
and the absolute lymphocyte count; however, in 
contrast with patients without CTCs, patients with ≥1 
CTC had significantly lower percentages of CD3+ T 
cells and TCR-activated CD8+ T cells that synthesized 
TNF-α and IFN-γ, and a higher percentage of 
T-regulatory lymphocytes (Table 3). Further, in 
comparison with patients with < 5 CTCs, patients 
with ≥5 CTCs had lower percentages of CD3+ T cells 
and CD3+CD4+ T cells, but a higher percentage of 
TCR-activated CD8+ T cells that synthesized IL-17. 
Patients with IBC with no CTCs had significantly 
lower absolute and relative lymphocyte counts, 
higher percentage of CD3+ T cells and lower 
percentage of CD4+ T cells that synthesized IL-4, 
compared to those of healthy normal donors. In 
multivariate analysis, tumor grade and percentage of 
CD3+ T cells were associated with the presence of ≥1 
CTCs (Table 4), while tumor grade, tumor stage, and 
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percentages of CD3+ T cells and TCR-activated CD8+ 
T cell synthesizing IL-17 were associated with the ≥5 
CTC status (Table 5). 
Prognostic value of CTC and T cell subsets in 
IBC 
At a median follow-up time of 19.4 months 
(range, 1.0-66.0 months), 42 patients (65.0%) had died. 
Patients with either ≥ 1 CTC or ≥ 5 CTCs had a 
significantly inferior overall survival (OS) [HR=2.48, p 
= 0.003 and HR=1.85, p = 0.045] than patients with no 
CTCs or with <5 CTCs, respectively (Figure 1A). 
Patients with “low” ALC and “low” percentages of 
CD4+ T cells, TCR-activated CD4+ T cells 
synthesizing IL-2, and TCR-activated CD8+ T cells 
synthesizing IL-2, TNF-α and/or IFN-γ had inferior 
survival than patients with “high” percentages of 
these cells (Table 6). In multivariate analysis, HER2 
status, hormone receptor status, and TCR-activated 
CD8+ T cells synthesizing IFN-γ were associated with 
overall survival, while CTCs had borderline 
significance (p = 0.059) (Table 7).  
In subsequent analysis, we combined the 
prognostic value of CTCs and immune cells. Patients 
with ≥5 CTCs and low percentages of all lymphocytes, 
CD3+CD4+ T cells and TCR-activated CD8+ T cells 
synthesizing IFN-γ had significantly worse survival 
compared with that of patients with <5 CTCs and 
high percentages of these immune cells. For example, 
patients with “low” TCR-activated CD8+ T cells 
synthesizing IFN-γ and ≥5 CTC had significantly 
worse OS compared to patients with “high” 
TCR-activated CD8+ T cells synthesizing IFN-γ  and < 
5 CTC. (HR = 3.60, 95% CI 1.32 – 9.87, p = 0.008) 
(Figure 1B). 
 
Table 4. Multivariate logistic regression model for the binary 
indicator of CTC ≥ 1 
Variable Odds ratio 95% CI Low 95% CI Upper P – value 
% CD3+ 
(continous variable) 
0.89 0.82 0.96 0.005 
Grade 
3 vs. 1 and 2 
3.48 1.02 11.84 0.046 
 
Table 5. Multivariate logistic regression model for the binary 
indicator of CTC ≥ 5 
Variable Odds ratio 95% CI Low 95% CI Upper P – value 
% CD3+ 
(continous variable) 
0.89 0.79 1.00 0.046 
% CD3+ CD4+ 
(continous variable) 
0.94 0.86 1.04 0.217 
% CD3+ CD8+IL-17+  
(continous variable) 
2.44 1.10 5.38 0.028 
Grade 
3 vs. 1 and 2 
14.60 1.42 150.27 0.024 
Stage 
metastatic vs. stage III  
52.94 1.10 2549.24 0.045 
Table 6. Prognostic value of CTCs and different subpopulations 
of T cells and their function on overall survival in IBC patients 
Variable Hazard ratio Low 95%CI Upper 95% CI P - value 
CTCs (≥1 vs. 0) 2.84 1.54 5.23 0.003 
     
CTCs (≥5 vs. < 5) 1.85 0.94 3.67 0.05 
     
Absolute lymphocyte 
count 
k/μL (low vs. high)* 
2.04 1.1 3.79 0.02 
     
CD3+  1.23 0.66 2.28 0.52 
CD3+ CD4+ 2.19 1.16 4.11 0.01 
CD3+ CD8+ 0.66 0.35 1.24 0.18 
CD4/CD8 ratio 1.76 0.92 3.33 0.07 
Treg in CD4+ 0.66 0.36 1.23 0.19 
     
CD3+ CD4+IFN-γ 1.48 0.75 2.94 0.26 
CD3+ CD4+TNF-α 1.69 0.85 3.36 0.13 
CD3+ CD4+IL-2 2.12 1.06 4.24 0.03 
CD3+ CD4+IL-4 1.08 0.55 2.13 0.83 
CD3+ CD4+IL-10 0.92 0.46 1.82 0.81 
CD3+ CD4+IL-17 0.88 0.45 1.75 0.72 
     
CD3+ CD8+IFN-γ 2.38 1.18 4.79 0.01 
CD3+ CD8+TNF-α 3.59 1.76 7.32 0.0001 
CD3+ CD8+IL-2 2.07 1.04 4.12 0.03 
CD3+ CD8+IL-4 1.31 0.66 2.59 0.44 
CD3+ CD8+IL-10 1.5 0.76 2.96 0.24 
CD3+ CD8+IL-17 1.39 0.27 7.3 0.65 
* all immune cells subpopulation were dichotomized as “low” or “high” based on 
median value of percentage of immunes cells in all patients. All hazard ratios are 
based on comparison of “low” vs. “high” groups. 
 
Table 7. Multivariate analysis of prognostic factors associated 
with overall survival. 
Variable HR  
(95% C.I.) 
P - value 
HER2 status 
Overexpressed vs. negative 
0.219 
(0.089 - 0.542) 
0.001 
HR status 
Positive for either vs. negative for both 
0.415  
(0.180 - 0.960) 
0.040 
CD3+ CD4+ 
High vs. low 
0.494  
(0.227 - 1.075) 
0.075 
CD3+ CD8+ IFN-γ 
High vs. low 
0.433  
(0.202 - 0.930) 
0.032 
 * all immune cells subpopulation were dichotomized as “low” or “high” based on 
median value of percentage of immunes cells in all patients. All hazard ratios are 
based on comparison of “low” vs. “high” groups. 
HR = hazard ratio. 
 
Discussion 
This prospective translational study confirmed 
our recent report on the prognostic value of CTCs in 
patients with IBC. [16]. Moreover, here we show for 
the first time that patients with IBC with CTCs (at 
least 1 CTC/7.5 mL of peripheral blood) have 
abnormalities in adaptive immunity as suggested by 
the lower percentages of both CD3+ T cells and 
CD3+CD4+ T-helper cells. We suggest that an inverse 
correlation between CD3+ T cells and CTCs is 
corresponding to impaired adaptive immunity in 
patients with detectable CTCs [14]. Importantly, this 
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inverse correlation is consistent for both stage III and 
metastatic IBC, including patients with mIBC who 
were treatment naïve. In contrast with the study by 
Gruber et al. of non-metastatic, non-IBC patients, we 
also found an inverse correlation between CTCs and 
CD4+ T cells in patients with IBC [22].  
In comparison to normal donors, all patients 
with IBC had a significantly lower ALC, which 
correlated with disease stage, with the lowest 
lymphocyte counts being observed in patients with 
mIBC who had received prior treatment; however, 
this could be partly due to the myelosuppresive effect 
of chemotherapy patients. Lymphocytes play an 
important role in antitumor immunity, and the ALC is 
associated with patients´ outcome in several types of 
cancers including breast cancer [37-41]. In a previous 
study, we observed that patients with metastatic 
breast cancer with <1000/μL lymphocytes have 
poorer prognosis compared to patients with a higher 
ALC and similar to this study, there was no 
association between peripheral blood lymphocytes 
and the number of CTCs [38]. In addition, we 
observed several other abnormalities in T cell 
numbers and their function in IBC patients, compared 
to normal donors (Table 2). Patients with mIBC had a 
higher percentage of T-regulatory cells compared to 
that of patients with stage III IBC as well as compared 
to that of normal donors, which is consistent with 
immunosuppression related to advanced stage of 
disease.  
 
 
 
Figure 1. Prognostic value of CTC (A) and combined prognostic value of CTC and TCR-activated CD8+ T cells synthesizing IFN-γ (B). Patients 
with “low” TCR-activated CD8+ T cells synthesizing IFN-γ and CTC ≥ 5 (group 3) had significantly worse survival (median OS = 10.5 months) compared to patients 
with “high” TCR-activated CD8+ T cells synthesizing IFN-γ and CTC < 5 (group 1) (median OS not reached). Patients with either “low” TCR-activated CD8+ T cells 
synthesizing IFN-γ and CTC < 5 (group 0) (median OS = 19.4 months) or “high” TCR-activated CD8+ T cells synthesizing IFN-γ and CTC ≥ 5 (group 4) (median 
OS = 24.9 months) had intermediate prognosis. TCR-activated CD8+ T cells s synthesizing IFN-γ were dichotomized as “low” or “high” based on median value of 
percentage of these cells in all patients. 
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In a further analysis of the CD4+ T-cell subsets in 
peripheral blood, we found that patients with mIBC 
had a higher proportion of T-regulatory cells than that 
of patients with stage III IBC. An increased 
T-regulatory cell frequency has been associated with 
advanced stages and poor prognosis in cancer 
patients [42]; however, this does not seem to be the 
case in breast cancer as patients with tumors 
overexpressing HER2 are believed to have a higher 
frequency of T-regulatory cells in peripheral blood, 
irrespective of stage of disease [43,44]. A more recent 
report showed that early breast cancer patients with 
HER2+ tumors were more likely to have an increased 
number of T-regulatory cells in peripheral blood 
compared with patients with HER2+ negative tumors 
[45] and that draining lymph nodes may also have a 
high frequency of these cells [46]. Collectively, these 
studies suggest that T-regulatory cells play a pivotal 
role in maintaining a pro-tumorigenic 
microenvironment [47] that might allow for the 
expansion of HER2+ CTCs. In our study, there was no 
correlation between expression of HER2+ in primary 
tumor and T-regulatory cells in peripheral blood; 
however, recent studies suggested that HER2+ 
amplification is present in CTCs from 15% to 30% in 
patients with HER2 negative primary tumor and from 
60% to 98% in patients with HER2 amplified primary 
tumor [48-50]. Therefore, we speculate that a positive 
correlation between CTCs and T-regulatory cells 
could reflect not only general dysfunction of adaptive 
immunity in patients with IBC who have poor 
prognosis disease, but also could be related to direct 
effect of T-regulatory cells that facilitate the 
dissemination of CTCs, thereby increasing their 
metastatic potential [51]. 
IL-17 is an inflammatory cytokine produced by 
CD4+ (Th17) and CD8+ (Tc17) T-cell subsets. Th17 
cells are CD4+ T cells that secrete IL-6, IL-17, and 
TNF-α, and have been implicated in inflammation 
and autoimmune disease [52]. Tc1 cells are CD8+ 
T-cells that produce IFN-γ and TNF-α, and destroy 
their target cell through perforin or Fas-mediated 
pathways [53-55]. On the other hand, Tc17 cells 
express low levels of granzyme B, perforin and FasL 
and are incapable of destroying tumor cell targets 
cells [55]. In our study, patients with IBC who had ≥5 
CTCs had a higher percentage of TCR-activated CD8+ 
T cells that synthesized IL-17. While these cells show 
antitumor activity in vitro with potential implications 
for the CD8+ T cell-based adoptive immunotherapy 
[56], in patients with breast cancer the higher 
percentage of these cells correlated with disease 
progression [57], consistent with our results.  
TCR-activated CD8+ T cells synthesizing IL-10 
represents another suppressor T-cell lineage [58, 59], 
but surprisingly patients with mIBC had a 
significantly lower percentage of these cells than in 
both normal donors and in patients with stage III IBC. 
We speculate, that in patients with mIBC, probably 
T-regulatory cells, but not TCR-activated CD8+ T cells 
synthesizing IL-10, represent the dominant pathway 
of immune tolerance. All patients with IBC (stage III 
IBC and mIBC) had a lower percentage of 
TCR-activated CD4+ T cells that synthesized IL-4 
compared to similar cells of normal donors, and this 
observation is consistent with a previous observation 
in patients with non-IBC breast cancer [60]. As IL-4 
influences the activity of lymphokine activated killer 
(LAK) and natural killer (NK) cells [61-63], a lower 
percentage of TCR-activated CD4+ T cells 
synthesizing IL-4 could be reflective of a 
dysfunctional immune system in patients with breast 
cancer.  
CTCs represent a heterogeneous population of 
cells with different phenotypes and biological value 
[18]. Experimental and clinical data suggest that the 
epithelial-to-mesenchymal transition (EMT) plays an 
important role in the generation of CTCs and the 
acquisition of resistance to therapy. Recent data 
showed that subpopulations of CTCs have partial or 
complete EMT phenotype [64-66]. EMT is closely 
linked to immunity and activation of the EMT 
program induces T-regulatory cells and impaired 
dendritic cells, suggesting that the 
immunosuppressive effect of EMT is consistent with 
our results of impaired adaptive immunity in patients 
with detectable CTCs [67].  
Emerging data suggest the prognostic value of 
immune cells in different types of cancer, including 
breast cancer. Infiltration of tumor with different 
subpopulations of immune cells is closely associated 
with prognosis and/or response to anticancer 
treatment [68-70]. In our study, we observed the 
prognostic value of several lymphocyte subsets 
(Table 6) and more importantly, we achieved an 
increased prognostic value of CTCs in combination 
with immune cells (Figure 1). These data suggest that 
the properties of the microenvironment in cancer 
patients contribute to prognosis beyond CTCs in 
peripheral blood. 
The main limitations of this study are sample 
size and patient population heterogeneity. To increase 
statistical power of analyses, we combined patients 
with stage III and metastatic IBC disease; however, we 
included disease stage in multivariate analyses to 
control for this confounder. Our results are applicable 
only to patients with IBC and similar studies in 
patients with non-IBC are warranted. Approximately 
half of the patients were pretreated with previous 
chemotherapy that could have affected study results 
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as well, especially due to decreases in absolute 
lymphocyte counts associated with prior 
chemotherapy. To assess any relationship between 
CTCs and immune cells, we performed multiple 
comparisons; therefore, our results are only 
hypothesis generating, despite their biological and 
clinical rationale and should be confirmed in further 
studies.  
In conclusion, in this study, we showed for the 
first time that patients with IBC with detectable CTCs 
had abnormalities in adaptive immunity. Based on 
these data, we suppose that observed associations 
between CTCs and T cells and their function could 
reflect results of direct interaction between CTCs and 
immune system in the peripheral blood. 
Alternatively, an increased CTC count could be a 
surrogate marker of more aggressive disease with an 
associated decrease in adaptive immunity and general 
dysfunction of immune system in inflammatory 
breast cancer. These data illustrate as well an inverse 
relationship between CTCs and adaptive immune 
cells in the peripheral blood microenvironment that 
could potentially impact tumor cell dissemination and 
initiation of the metastatic cascade. Moreover, 
immune cell profiling could add further prognostic 
value to CTCs in patients with inflammatory breast 
cancer. 
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